New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2012
16:15 EDTYPF, WG, GSK, GRPN, KERX, THRX, AVPOn The Fly: Closing Wrap
Stocks on Wall Street were higher after manufacturing reports in the U.S. and China indicated expansion. Stock futures traded below fair value for most of the pre-market trading session leading to a lower open for the broader market. The weakness was attributed to a high unemployment reading and a lackluster PMI report out of Europe. The market reversed its course and moved into positive territory following the slightly better than expected ISM manufacturing report here in the U.S. Once in positive territory the market moved quickly, but its advance stalled at a resistance level for the S&P. The move broadened out with the Nasdaq ending the day as the leading major index... ECONOMIC EVENTS: Domestically, the ISM manufacturing reading of 53.4 exceeded expectations for a 53.0 reading. Construction spending in February was down 1.1%, versus the expected increase of 0.6%. Internationally, an official reading of China's PMI rose to 53.1 while Markit's Eurozone manufacturing PMI fell to 47.7... MARKET NEWS: Avon Products (AVP) rejected the increased bid of $23.25 per share from fragrance-maker Coty. Avon shares rose $3.34, or 17.25%, to $22.70 following the announcement of the sweetened offer though Coty said it will not go hostile with its buyout plan... Groupon (GRPN) shares slid almost 17%, to $15.27, after the company announced weakness in its internal controls and revised its Q4 results lower... MAJOR MOVERS: Among the notable gainers were Willbros Group (WG), up 69c, or 21.30%, to $3.93, after its Q4 revenues beat expectations, and Theravance (THRX), up $3.79, or 19.44%, to $23.29, after GlaxoSmithKline (GSK) moved to raise its stake in the company to 26.8% with the purchase of 10M shares. Noteworthy losers included YPF SA (YPF), down $4.40, or 15.49%, to $24.01, following a downgrade at Merrill Lynch and a report that Argentina's government will take control of the company, and Keryx Biopharmaceuticals (KERX), down $3.24, or 65.06%, to $1.74, after the company announced that a trial for its lead drug missed its primary endpoint... INDICES: The Dow gained 52.45, or 0.40%, to 13,264.49; the Nasdaq added 28.13, or 0.91%, to 3,119.70; and the S&P 500 rose 10.43, or 0.74%, to 1,418.90.
News For AVP;GRPN;WG;THRX;GSK;YPF;KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 23, 2015
05:48 EDTAVPStocks with implied volatility movement; AVP FXCM
Stocks with implied volatility movement; Avon Products (AVP) 91, FXCM (FXCM) 194 according to iVolatility.
January 22, 2015
16:27 EDTAVPOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTAVPOptions Update; January 22, 2015
iPath S&P 500 VIX Short-Term Futures down 2.13 to 31.32 Option volume leaders: AAPL TSLA TWTR AMZN FB FXCM AVP BAC according to Track Data.
13:29 EDTAVPAvon Products jumps after report of talks with private equity firm
Shares of Avon Products (AVP) are rising in afternoon trading after dealReporter said the company has been holding talks with private equity firm TPG Capital, citing industry sources. Avon canceled out of the Consumer Analyst Group of New York conference coming up in February, according to Bloomberg. Conference cancellations often lead investors to speculate whether a company is engaged in merger or acquisition talks. TPG declined to comment and Avon did not immediately respond to Bloomberg's request for a comment, the news service added. Avon shares are up 14.4% to $8.65 in afternoon trading following the report.
13:16 EDTAVPAvon Products calls active on discussions with TPG Capital report
Avon Products January weekly 7 and 8 calls are active on total call volume of 9,600 contracts (700 puts) on the company has been in discussions with TPG Capital, dealReporter says. January weekly call option implied volatlity is at 188, February is at 69; compared to its 26-week average of 39 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
13:12 EDTAVPAvon Products up 15% after rumors of discussions with TPG Capital
13:05 EDTAVPAvon Products has been in discussions with TPG Capital, dealReporter says
Subscribe for More Information
13:03 EDTAVPAvon Products moves up on comments by dealReporter
06:32 EDTGRPNBlue Calypso files motion to lift stay in patent infringement cases and appeal
Blue Calypso (BCYP) announced that it has filed a motion in the Eastern District of Texas to lift the negotiated stay on the pending patent infringement litigation between the Company and Groupon (GRPN), Yelp (YELP), Foursquare and IZEA.PK. The Company has also filed notices of appeal at the Federal Circuit Court of Appeals in each of the Covered Business Method Review cases at the Patent Trial and Appeals Board. On January 14, 2014, the parties agreed to stay the litigation in the Eastern District pending the decisions from the PTAB as to validity of the patents. As a part of agreeing to join the stay, the parties jointly agreed to ask the Court to lift the stay and for an expedited litigation schedule if any of the asserted claims were held valid by the PTAB. The PTAB now has confirmed the validity of twenty-eight claims and Blue Calypso, through its counsel, has asked the Court to lift the stay according to the agreement. The defendants refused to participate in the motion to lift the stay as previously agreed, and have instead asked the Court to leave the stay in place in a separate motion.
January 21, 2015
19:55 EDTKERXKeryx 9.17M share Secondary priced at $12.00
The deal size was raised to 9.17M shares from 7.2M shares. JPMorgan acted as sole book running manager for the offering.
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 20, 2015
18:30 EDTKERXOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTKERXKeryx files to sell $100M in common stock
J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
06:09 EDTAVPAvon Products implied volatility of 76 at upper end of index mean range
Subscribe for More Information
January 16, 2015
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
January 15, 2015
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
10:29 EDTAVP, GRPNOptions with increasing implied volatility
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
08:08 EDTGRPNGroupon upgraded at Evercore ISI
Subscribe for More Information
06:15 EDTGRPNGroupon upgraded to Hold from Sell at Evercore ISI
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use